We aimed to investigate atypical papillary renal cell carcinoma (PRCC) presenting with early contrast enhancement and late washout and to investigate the correlation between the CT attenuation value of the corticomedullary phase (CMP) of contrast-enhanced CT in PRCCs and the endothelial cell counts of these tumors.
In this brief correspondence, we evaluate the potential impact of pivoting from face-to-face supervised to unsupervised home-based exercise programmes to contextualise the coronavirus disease 2019 (COVID-19) pandemic in prostate cancer patients.
Intermediate-risk prostate cancer regroups heterogeneous patients with different oncologic outcomes. Aim of the study is to validate a novel intermediate-risk subclassification ("magnetic resonance imaging [MRI] subclassification") that defines favorable and unfavorable diseases based on multiparametric MRI parameters and compare it to NCCN and AUA intermediate-risk subclassifications.
The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies approved since 2016 that target programmed cell death protein 1 or programmed death ligand-1 for the treatment of metastatic and refractory bladder cancer is an outstanding achievement.
To assess the true cumulative morbidity after RC by implementing the Comprehensive Complication Index (CCI) over a 90-day period, since recent evidence suggests underreporting of the cumulative morbidity after radical cystectomy (RC) with inconsistent complication rates when reported with conventional reporting systems.
Screening across a multitude of normal and malignant tissues revealed an enhanced expression of lymphocyte antigen 6 superfamily member D (LY6D) in squamous epithelium and urothelium, as well as in malignancies derived therefrom.
Cancer immune plays a critical role in cancer progression. Tumour immunology and immunotherapy are one of the exciting areas in bladder cancer research. In this study, we aimed to develop an immune-related gene signature to improve the prognostic prediction of bladder cancer.
This paper was part of an initiative from the Journal of Sexual Medicine to explore the methodological aspects of sexual medicine studies. It was motivated by the perception of protocol heterogeneity in the literature regarding the conduct of Penile Duplex Doppler ultrasound (PDDU). As a result, the interpretation and validity of the results is difficult.
Highlighting the unprecedented impact of a global pandemic on clinical trials in urological oncology, our study, published in the World Journal of Urology,1 provides a timely analysis of the need for a new perspective in a necessarily protocol-driven arena.
‒ Significant Reduction in Death Observed in Patients Who Received Immunotherapy and Commonly Prescribed Oral Treatments, Regardless of Treatment Order ‒ San Francisco, CA (UroToday.com) — Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced the publication of an analysis examining real-world survival outcomes in men with metastatic castrate-resistant prostate cancer […]
